Ms. Morris was most recently the chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda and an Initial Public Offering of $90 million. She also raised private C and D rounds of $100 million.

Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development.

In addition to Syndax, Ms. Morris serves on the board of directors of BIO, Neovacs, MediciNova and the Foundation for Research and Development, Medical University of South Carolina. She received her bachelor’s degree in biology and chemistry from Carlow College.

Dr. Goodenow has over 20 years of experience in the biopharmaceutical industry spanning R&D, product launch, marketing, intellectual property, and business development for drugs and drug-device combinations.

He was formerly vice president of corporate development for Inovio Biomedical Corporation, where he was responsible for partnering and commercialization of the company’s oncology and vaccine platforms. He also held key management positions at Aventis in both corporate marketing and business development for oncology during the initial commercialization of Taxotere®, as well as in R&D for Baxter Biotech.

Dr. Goodenow received his bachelor’s degree in biochemistry from the University of California, Berkeley, a Ph.D. in biophysics from Stanford University, and completed postdoctoral training at Caltech in the biology division.

Miranda Rees has over 30 years of experience in global drug development. She has led multidisciplinary project teams in both large pharmaceutical and small biotechnology companies and functional areas including biometrics, integrated program management and regulatory affairs.

Prior to joining Syndax Ms. Rees was vice president product development at Novacea, where she led the project team as the company grew from a ground zero start-up to a Phase 3 ready oncology-focused development company. Formerly Ms. Rees was a global project team leader at Roche where she led international project teams through the successful completion of global market licensing applications. Having been trained as a biostatistician, she worked as a director of statistics at Roche and before that at Syntex, Glaxo and Beecham Pharmaceuticals.

Ms. Rees earned a bachelor’s degree in mathematics and statistics from the University of Reading, England, and a master’s degree in biostatistics from Columbia University.

Dr. Ordentlich, a co-founder of Syndax, is the Vice President of Translational Medicine, responsible for the scientific rationale and direction of research efforts related to the company's projects.

Prior to Syndax, Dr. Ordentlich was a scientist at the Salk Institute in La Jolla, California, working with Dr. Ronald M. Evans to identify small molecules as potential therapeutics and evaluating synergistic combinations of histone deacetylase inhibitors and nuclear receptor ligands.

Dr. Ordentlich spent five years at X-Ceptor Therapeutics, a drug discovery company focused on the identification and therapeutic application of novel and selective modulators of nuclear hormone receptors, where he led a group in assay development, high-throughput screening, and lead optimization.

Dr. Ordentlich did his postdoctoral fellowship with Dr. Ronald M. Evans, investigating the molecular mechanisms involved in nuclear hormone receptor signaling. His work, along with that of Dr. Michael Downes and other members of the Evans laboratory, led to the identification and characterization of several proteins involved in nuclear receptor regulation including histone deacetylases 5 and 7 (HDAC5 and HDAC7) and novel isoforms of the co-repressors SMRT and SHARP.

Dr. Ordentlich received his bachelor’s degree in biochemistry and Ph.D. in immunology from the University of Pennsylvania.

Jeannette Hasapidis brings to Syndax more than 16 years experience in clinical operations and project management. Early in her career, she worked for Parexel International, one of the leading contract research organizations worldwide, and since has worked predominantly in clinical trial management.

Immediately prior to joining Syndax, Ms. Hasapidis was the director of clinical operations at Xanthus Pharmaceuticals, a biopharmaceutical company developing small-molecule therapeutics for the treatment of cancer and autoimmune disorders. There she led an international team of 10 employees responsible for running the phase 1, 2 and 3 trials in both hematological malignancies and solid tumors. Prior to Xanthus at V. I. Technologies, in the role of associate director of clinical operations, she managed a department conducting phase 1 and 2 clinical trials evaluating biotechnology-based products to improve the safety of blood transfusion. While at V.I. Technologies, she participated in two FDA audit preparations and the NDA filing for Lanreotide Autogel®. Ms. Hasapidis received her bachelor’s degree in education at the University of Massachusetts.

John Pallies has over a decade of experience in biotech, high-tech start-ups and management consulting focused on developing corporate and financial infrastructure and managing multiple business operations.

Immediately prior to joining Syndax, Mr. Pallies was controller and director of finance at Cerimon Pharmaceuticals, a late-stage biopharmaceutical start-up focused on autoimmune disease, inflammation, and pain. Prior to that Mr. Pallies spent five years at Akamai Technologies, a $7 billion high-tech company providing content and applications delivery over the internet, where he ultimately served as the director of financial operations. He oversaw operational activities related to financial systems, including invoicing, commissions and payables at a number of start-up companies. In addition, Mr. Pallies worked as a management consultant at Arthur Anderson where he focused on business operations consulting.

Mr. Pallies holds a bachelor’s degree in marketing from Boston College and an M.B.A. from The Carroll School of Management at Boston College.